{
    "organizations": [],
    "uuid": "bbb2f6ab17d22410405b3f809b43c84f223963ea",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-syndax-announces-updated-results-f/brief-syndax-announces-updated-results-from-phase-2-encore-601-trial-of-entinostat-in-combination-with-keytruda-idUSASC0A2QS",
    "ord_in_thread": 0,
    "title": "BRIEF-Syndax Announces Updated Results From Phase 2 Encore 601 Trial Of Entinostat In Combination With Keytruda®",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 17 (Reuters) - Syndax Pharmaceuticals Inc:\n* SYNDAX ANNOUNCES UPDATED RESULTS FROM PHASE 2 ENCORE 601 TRIAL OF ENTINOSTAT IN COMBINATION WITH KEYTRUDA® (PEMBROLIZUMAB)\n* SYNDAX PHARMACEUTICALS INC - POTENTIAL REGISTRATION PATHWAY IDENTIFIED IN NSCLC; NEXT TRIAL ANTICIPATED TO COMMENCE BY END OF 2018\n* SYNDAX PHARMACEUTICALS INC - CONFIRMED OBJECTIVE RESPONSES WITH COMBINATION REGIMEN HAVE BEEN OBSERVED ACROSS ALL COHORTS IN PHASE 2 TRIAL Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)\n ",
    "published": "2018-05-17T19:13:00.000+03:00",
    "crawled": "2018-05-18T19:49:33.037+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "syndax",
        "pharmaceutical",
        "inc",
        "syndax",
        "announces",
        "updated",
        "result",
        "phase",
        "encore",
        "trial",
        "entinostat",
        "combination",
        "pembrolizumab",
        "syndax",
        "pharmaceutical",
        "inc",
        "potential",
        "registration",
        "pathway",
        "identified",
        "nsclc",
        "next",
        "trial",
        "anticipated",
        "commence",
        "end",
        "syndax",
        "pharmaceutical",
        "inc",
        "confirmed",
        "objective",
        "response",
        "combination",
        "regimen",
        "observed",
        "across",
        "cohort",
        "phase",
        "trial",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}